|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/343 | (2006.01) |
| A61K 45/06 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 31/343 | (2013.01) | ||
| A61P 25/24 | (2006.01) | ||
| A61P 25/24 | (2018.01) |
| (11) | Number of the document | 3661494 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18755664.2 |
| Date of filing the European patent application | 2018-08-02 | |
| (97) | Date of publication of the European application | 2020-06-10 |
| (45) | Date of publication and mention of the grant of the patent | 2023-10-11 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2018/044995 |
| Date | 2018-08-02 |
| (87) | Number | WO 2019/028245 |
| Date | 2019-02-07 |
| (30) | Number | Date | Country code |
| 201762540200 P | 2017-08-02 | US |
| (72) |
POLYMEROPOULOS, Mihael , US
POLYMEROPOULOS, Christos , US
XIAO, Changfu , US
|
| (73) |
Vanda Pharmaceuticals Inc. ,
2200 Pennsylvania Avenue NW
Suite 300-E, Washington, DC 20037,
US
|
| (54) | USE OF TASIMELTEON FOR THE TREATMENT OF AFFECTIVE DISORDERS IN MAJORITY BLACK AFRICAN PATIENTS |
| USE OF TASIMELTEON FOR THE TREATMENT OF AFFECTIVE DISORDERS IN MAJORITY BLACK AFRICAN PATIENTS |